Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

NCT07498907 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

192

Enrollment

OTHER

Sponsor class

Conditions

Upper Tract Urothelial Carcinoma

Interventions

DRUG: Disitamab Vedotin (RC48)
RADIATION: radiotherapy
DRUG: Gemcitabine (1000 mg/m2)
DRUG: carboplatin

Sponsor

Peking University First Hospital

Collaborators

[object Object]